Genetically induced retinal degeneration leads to changes in metabotropic glutamate receptor expression

Effect of metabotropic glutamate receptor 6 on cell morphology and melanosome transfer in melanocytes

The melanosome transfer pathway from melanocytes to keratinocytes has been extensively investigated; however, the underlying molecular mechanisms remain unclear. Therefore, the function of metabotropic glutamate receptor 6 (mGluR6) in the control of melanocyte-to-keratinocyte melanosome transfer, intracellular calcium levels in melanocytes, and the formation of filopodia were explored in this study. Primary melanocytes and keratinocytes were isolated from human foreskin samples. mGluR6 expression was suppressed using lentiviral-mediated short hairpin RNA (shRNA). Scanning electron microscopy (SEM), confocal laser scanning microscopy (CLSM), flow cytometry, and western blot analyses were used to assess filopodia formation, cytoskeletal organization, and melanosome transfer. We found that melanocytes expressed mGluR6 and that mGluR6 knockdown influenced the establishment of dendritic formation, melanocyte filopodia, and microphthalmia-associated transcription factors. Similarly, the efficiency of melanosome transfer from melanocytes to keratinocytes was reduced. According to these findings, melanosome transfer between melanocytes and keratinocytes mostly occurs by filopodia delivery, and mGluR6 directly influences melanosome transfer by altering melanocyte morphology. Comprehensive knowledge of melanosome transfer is essential when developing therapies for skin illnesses characterized by hyperpigmentation or hypopigmentation.

Optogenetics for visual restoration: From proof of principle to translational challenges

Degenerative retinal disorders are a diverse family of diseases commonly leading to irreversible photoreceptor death, while leaving the inner retina relatively intact. Over recent years, innovative gene replacement therapies aiming to halt the progression of certain inherited retinal disorders have made their way into clinics. By rendering surviving retinal neurons light sensitive optogenetic gene therapy now offers a feasible treatment option that can restore lost vision, even in late disease stages and widely independent of the underlying cause of degeneration. Since proof-of-concept almost fifteen years ago, this field has rapidly evolved and a detailed first report on a treated patient has recently been published. In this article, we provide a review of optogenetic approaches for vision restoration. We discuss the currently available optogenetic tools and their relative advantages and disadvantages. Possible cellular targets will be discussed and we will address the question how retinal remodelling may affect the choice of the target and to what extent it may limit the outcomes of optogenetic vision restoration. Finally, we will analyse the evidence for and against optogenetic tool mediated toxicity and will discuss the challenges associated with clinical translation of this promising therapeutic concept.

Plasticity of TRPM1 expression and localization in the wild type and degenerating mouse retina

The light response in retinal ON bipolar cells is associated with disinhibition of current flow through cation channels recently identified as type 1 members of the melastatin transient receptor potential (TRPM) family. We determined the developmental expression of Trpm1 in the wild type C57BL/6, DBA/2J, DBA2J-Gpnmb mouse retinas and in Pde6brd1 retinas characterized by degeneration of rod photoreceptors. Trpm1 mRNA in wild type retinas was low at birth but exhibited progressive increases in abundance up to early adulthood at postnatal day 21 (P21). Retinal Trpm1 mRNA content did not decrease following loss of photoreceptors. At P21, TRPM1-immunopositive perikarya migrated into the outer nuclear layer. The TRPM1 protein was trafficked to discrete postsynaptic puncta in wild type retinas whereas in adult Pde6brd1 mouse retinas, TRPM1 translocated to bipolar perikarya and bar-like structures in the distal inner nuclear layer. These findings show that expression and localization of the TRPM1 in the mouse retina is plastic, modulated by use-dependence and availability of sustained excitatory input.

Ionic dysregulatory phenotyping of pathologic retinal thinning with manganese-enhanced MRI

PURPOSE

To test the hypothesis that manganese-enhanced MRI (MEMRI) provides a sensitive and robust measure of an important retinal ionic dysregulatory phenotype in pathologic retinal thinning.

METHODS

Four hours after intraperitoneal MnCl(2) injection, high-resolution MEMRI data were collected from overnight dark-adapted male control Sprague-Dawley and albino Royal College of Surgeons rats before (at development stage postnatal day [P] 17) and during photoreceptor degeneration (P36 and P57). In separate experiments, control rats, with and without repetitive hypoxic preconditioning, were subjected to high IOP (100 mm Hg) for 60 minutes followed by 24 hours or 7 days of reperfusion (e.g., ischemia/reperfusion). Central retinal thickness and intraretinal ion activity were measured from the MEMRI data. Histology examination was also performed to confirm retinal damage.

RESULTS

In two different neurodegenerative models, MEMRI revealed first-time evidence for changes (P < 0.05) in intraretinal ion regulation before and during pathologic, but not (P > 0.05) developmental, retinal thinning. This phenotype was significantly altered by a neuroprotective repetitive hypoxic preconditioning protocol.

CONCLUSIONS

MEMRI and a nontoxic systemic dose of MnCl(2) provided an objective, noninvasive measure of an ionic deregulatory phenotype that appears useful for improved early diagnosis and treatment prognosis in a range of neurodegenerative diseases and their treatment.